Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Di Pietro

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Bioengineering (Basel, Switzerland)|July 29, 2025
Aerosol Jet Printing for Neuroprosthetic Device DevelopmentLander De Waele, Massimo Di Pietro, Stefano Perilli, et al.
AIDS (London, England)|February 4, 2010
Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabineRenato Maserati, Annalisa De Silvestri, Alessia Uglietti, et al.
The Journal of Infectious Diseases|April 6, 2006
Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapyAndrea De Luca, Simona Di Giambenedetto, Laura Romano, et al.
BMC Infectious Diseases|March 8, 2017
Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort studyElena Raffetti, Francesco Donato, Salvatore Casari, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 27, 2018
Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 TrialAdriana Ammassari, Wolfgang Stöhr, Andrea Antinori, et al.
Intensive Care Medicine|November 11, 2017
Potential role of IgM-enriched immunoglobulin as adjuvant treatment for invasive meningococcal diseaseCarlo Tascini, Fiorentino Fraganza, Francesca Salani, et al.
Plos One|May 29, 2015
Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAARTGiuseppe Lapadula, Liliane Chatenoud, Andrea Gori, et al.
Antiviral Therapy|July 22, 2006
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapyGiuseppe Lapadula, Carlo Torti, Giuseppe Paraninfo, et al.
Antiviral Therapy|October 12, 2007
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3Giuseppe Lapadula, Carlo Torti, Franco Maggiolo, et al.
HIV Clinical Trials|July 11, 2007
Predictors of AIDS-defining events among advanced naïve patients after HAARTCarlo Torti, Giuseppe Lapadula, Franco Maggiolo, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Bioengineering (Basel, Switzerland)|July 29, 2025
Aerosol Jet Printing for Neuroprosthetic Device DevelopmentLander De Waele, Massimo Di Pietro, Stefano Perilli, et al.
AIDS (London, England)|February 4, 2010
Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabineRenato Maserati, Annalisa De Silvestri, Alessia Uglietti, et al.
The Journal of Infectious Diseases|April 6, 2006
Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapyAndrea De Luca, Simona Di Giambenedetto, Laura Romano, et al.
BMC Infectious Diseases|March 8, 2017
Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort studyElena Raffetti, Francesco Donato, Salvatore Casari, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 27, 2018
Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 TrialAdriana Ammassari, Wolfgang Stöhr, Andrea Antinori, et al.
Intensive Care Medicine|November 11, 2017
Potential role of IgM-enriched immunoglobulin as adjuvant treatment for invasive meningococcal diseaseCarlo Tascini, Fiorentino Fraganza, Francesca Salani, et al.
Plos One|May 29, 2015
Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAARTGiuseppe Lapadula, Liliane Chatenoud, Andrea Gori, et al.
Antiviral Therapy|July 22, 2006
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapyGiuseppe Lapadula, Carlo Torti, Giuseppe Paraninfo, et al.
Antiviral Therapy|October 12, 2007
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3Giuseppe Lapadula, Carlo Torti, Franco Maggiolo, et al.
HIV Clinical Trials|July 11, 2007
Predictors of AIDS-defining events among advanced naïve patients after HAARTCarlo Torti, Giuseppe Lapadula, Franco Maggiolo, et al.
Pageof 6